Skip to main content
. 2014 Oct 7;15:390. doi: 10.1186/1745-6215-15-390

Figure 1.

Figure 1

Study design. Arm 1: ER niacin administration begins at week 0 and ends at week 24 (defined as ‘immediate use’ arm). Arm 2: ER niacin administration begins after the week 24 visit and ends at week 48 (defined as ‘deferred use’ arm). ART, Antiretroviral therapy; ER, extended-release.